Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis Sicca
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
This study evaluates the efficacy and safety of 2 doses of pimecrolimus (0.3% and 1%)
ophthalmic suspension in a moderate to severe population of keratoconjunctivitis sicca (KCS,
dry eye syndrome) patients.